Evidence map›Paper›PMID 32027039›Full record

ArticleAllergy2020

Maternal ω3 docosapentaenoic acid inhibits infant allergic dermatitis through TRAIL-expressing plasmacytoid dendritic cells in mice.

So-Ichiro Hirata, Takahiro Nagatake, Kento Sawane, Koji Hosomi, Tetsuya Honda, Sachiko Ono, Noriko Shibuya, Emiko Saito, Jun Adachi, Yuichi Abe and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Allergy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

So-Ichiro HirataLaboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Japan.ORCID 0000-0002-9503-4646
Takahiro NagatakeLaboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Japan.
Kento SawaneLaboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Japan.
Koji HosomiLaboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Japan.
Tetsuya HondaDepartment of Dermatology, Kyoto University Graduate School of Medicine, Kyoto-city, Japan.
Sachiko OnoDepartment of Dermatology, Kyoto University Graduate School of Medicine, Kyoto-city, Japan.
Noriko ShibuyaDepartment of Pediatrics, Maternal & Child Health Center, Aiiku Clinic, Tokyo, Japan.
Emiko SaitoDepartment of Human Nutrition, Tokyo Kasei Gakuin University, Tokyo, Japan.
Jun AdachiLaboratory of Proteome Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Japan.
Yuichi AbeLaboratory of Proteome Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Japan.
Junko IsoyamaLaboratory of Proteome Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Japan.
Hidehiko SuzukiLaboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Japan.
Ayu MatsunagaLaboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Japan.
Takeshi TomonagaLaboratory of Proteome Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Japan.
Hiroshi KiyonoInternational Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kenji KabashimaDepartment of Dermatology, Kyoto University Graduate School of Medicine, Kyoto-city, Japan.
Makoto AritaLaboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences, Yokohama-city, Japan.ORCID 0000-0001-9902-0463
Jun KunisawaLaboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-city, Japan.ORCID 0000-0003-4901-1125
National Institute of Biomedical Innovation, Health and Nutrition · JPKyoto University · JPOsaka Gakuin University · JPKeio University · JPLa Jolla Institute for Immunology · USTokyo Kasei Gakuin University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMaternal dietary exposures are considered to influence the development of infant allergies through changes in the composition of breast milk. Cohort studies have shown that ω3 polyunsaturated fatty acids (PUFAs) in breast milk may have a beneficial effect on the preventing of allergies in infants; however, the underlying mechanisms remain to be investigated. We investigated how the maternal intake of dietary ω3 PUFAs affects fatty acid profiles in the breast milk and their pups and reduced the incidence of allergic diseases in the pups.

methodsContact hypersensitivity (CHS) induced by 2,4-dinitrofluorobenzene (DNFB) and fluorescein isothiocyanate was applied to the skin in pups reared by mother maintained with diets mainly containing ω3 or ω6 PUFAs. Skin inflammation, immune cell populations, and expression levels of immunomodulatory molecules in pups and/or human cell line were investigated by using flow cytometric, immunohistologic, and quantitative RT-PCR analyses. ω3 PUFA metabolites in breast milk and infant's serum were evaluated by lipidomics analysis using LC-MS/MS.

resultsWe show that maternal intake of linseed oil, containing abundant ω3 α-linolenic acid, resulted in the increased levels of ω3 docosapentaenoic acid (DPA) and its 14-lipoxygenation products in the breast milk of mouse dams; these metabolites increased the expression of TNF-related apoptosis-inducing ligand (TRAIL) on plasmacytoid dendritic cells (pDCs) in their pups and thus inhibited infant CHS. Indeed, the administration of DPA-derived 14-lipoxygenation products to mouse pups ameliorated their DNFB CHS.

conclusionThese findings suggest that an inhibitory mechanism in infant skin allergy is induced through maternal metabolism of dietary ω3 PUFAs in mice.

Indexed as

Fatty Acids, Omega-3TNF-Related Apoptosis-Inducing LigandAnimalsChromatography, LiquidDendritic CellsFatty Acids, UnsaturatedMiceTandem Mass Spectrometrydocosapentaenoic acidFatty Acids, Omega-3Fatty Acids, UnsaturatedTNF-Related Apoptosis-Inducing Ligand14-lipoxygenationbreast milkinfant allergyTRAILω3 DPA

Identifiers

PMID32027039
PMCPMC7496639
OpenAlexW3004743087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.